Skip to main content

Table 5 Endpoints after 24 and 48 weeks of treatment

From: Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Outcomes

Median (IQR)

P

24/48 weeks

Baseline

Week 24

Week 48

CD4+ cell count

245 (129–400)

311 (239–522)

378 (252–559)

<0.001*

HIV-1 RNA viral load

22,600 (3590–75,797)

<50 (<50–82)

<50 (<50–85)

<0.001*

Cholesterol (mg/dL)

167 (364–195)

174 (156–214)

185 (150–214)

0.004/<0.001

Triglycerides (mg/dL)

186 (135–260)

197 (148–271)

220 (162–305)

0.465/0.076

Creatinine (mg/dL)

0.86 (0.70–1.0)

0.9 (0.8–1.07)

0.9 (0.8–1.05)

<0.001*

  1. * At both 24 and 48 weeks